CLINICAL TRIAL SUMMARY

MDACC Study No:2014-0152 (clinicaltrials.gov NCT No: NCT02071927)
Title:A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Relapsed and/or Treatment-Refractory Leukemia and IDH-Mutated Myelodysplastic Syndrome
Principal Investigator:Marina Konopleva
Treatment Agent:CB-839
Study Status:Open
Study Description:The goal of Part I of this clinical research study is to find the highest
tolerable dose of CB-839 that can be given to patients with relapsed or
refractory AML or ALL.

The goal of Part II of this study is to learn if the dose found in Part 1 of
the study can help to control the disease.

The safety of the study drug will be studied in both parts of this study.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:CB-839
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Calithera Biosciences
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Marina Konopleva
Dept:Leukemia
For Clinical Trial Enrollment:713-794-1628
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults